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metabolised in the liver via the P450 cytochrome system, a
pathway shared with many other compounds. This creates
a risk for drug/drug interactions and the potential to
modify the efficacy and/or toxicity of the agents involved.
Particular attention should be given to the concomitant use
of NNRTls and rifampicin, oral contraceptives and the
protease inhibitor family of antiretrovirals. Rifampicin
reduces NNRTI concentrations by approximately 30%.
While the clinical significance of this interaction remains
uncertain, some authorities recommend increasing the
dose of efavirenz to 800 mg at night in patients with a
mass of > 60 kg. There are no clear recommendations for
adjusting the dose of nevirapine. All NNRTls reduce the
plasma concentrations of oestrogen-containing oral
contraceptives, so women of childbearing potential should
be advised to switch to an injec able contraceptive or one
of the newer progestogenic oral preparations. NNRTls
reduce the plasma concentrations of protease inhibitors to
potentially subtherapeutic levels that can be corrected by
dosage adjustments or the addition of a boosting dose of
ritonavir.
Structure ofHIV -1 RT
Certain drug-related toxlclt,es are common to both
nevirapine and efavirenz, including hypersensitivity
syndromes of varying severity, the most common
manifestations being erythema multiforme and hepatitis.
A critical evaluation of published literature confirms that
skin eruptions - including the very rare Stevens-Johnson
syndrome - occur with the use of either compound.
Induction of hepatic transaminases is a common finding
Or Steven Miller, MB BCh, DTMH, FFPath, MMed, MRCPath,
Dip HN Med (Un delivered a presentation on the non-
nucleoside reverse transcriptase inhibitors [NNRTls) to the
HIV Clinicians Society in Johannesburg on 31 July 2003. He
confirmed the clinical usefulness of nevirapine and
efavirenz and provided data that demonstrated comparable
potency and efficacy of these agents. He highlighted the
results of the recent 2NN study, which confirm the clinical
equivalence of nevirapine and efavirenz. This prospective,
randomised clinical trial is the first head-to-head
comparison of nevirapine and efavirenz and included 1 216
patients in 17 countries (including South Africa) on 6
continents. The study showed that, after 48 weeks of
treatment, there was no significant difference in the
percentage of people who achieved virological success
between the nevirapine and efavirenz arms. Serious drug
toxicities were rare and were generally encountered at
similar, low rates.
Both nevirapine and efavirenz possess excellent
bioavailability and rapidly attain high plasma
concentrations with recommended dosing schedules. All
NNRTls are biologically active in the form in which they are
administered. They therefore inhibit free virions in the
plasma and tissue fiuids, as well as virus within cells. This
mode of action is different from the nucleoside drugs,
which are ingested as pro-drugs, require intracellular
activation and inhibit only cell-associated virus. Tissue
penetration of the NNRTls is good and their ability to cross
the placenta is one of the rationales for the much-
publicised use of nevirapine in prevention of mother-to-
child HIV transmission (PMTcn. Although nevirapine is only
one of several regimens that are safe and effective in
PMTCT, the low cost and simplicity of the regimen have
made it an attractive strategy in resource-constrained
settings. Nevirapine crosses the blood/brain barrier with
ease and penetrates well into brain tissue, while efavirenz
achieves far lower concentrations in the central nervous
system. Paradoxically, efavirenz is associated with
significant neuropsychiatric adverse effects while
nevirapine is not.
Both nevirapine and efavirenz are highly protein-bound,
which results in a long half-life that permits simple dosing
regimens and once-daily administration. Both drugs are
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among people using nevirapine and efavirenz. On its own,
this does not necessarily constitute hepatitis. True hepatitis
is a clinical illness that comprises constitutional
manifestations, jaundice and elevation of hepatic
transaminases to greater than 3 - 5 times the upper limit
of normal. Individuals who abuse
alcohol and/or are positive for
hepatitis 8 surface antigen and/or .',,' ,
hepatitis Cappear to be most at risk. ."
Since the risk of hepatitis in these
specific at-risk groups appears to be
greater with nevirapine, many experts
prefer efavirenz in this particular
setting provided there are no
contraindications to the use of the
agent, e.g. pregnancy.
Dyslipidaemia has recently emerged
as a major metabolic problem among
individuals taking antiretroviral
therapy. The nucleoside drugs and
protease inhibitors are the most
commonly implicated agents. Clinical
studies in this setting confirm that
switching from aprotease inhibitor to
nevirapine generally proves beneficial
providing viral susceptibility to
nevirapine has been assured.
Switching from aprotease inhibitor to
efavirenz does not ameliorate
dyslipidaemia. Among individuals
receiving long-term NNRTI-based
therapy, efavirenz has been
demonstrated to reduce high-density
lipoprotein (HDL) cholesterol, a
pattern that is potentially
atherogenic. Conversely, nevirapine
consistently raises HDL cholesterol,
which has the potential to confer
protection against cardiovascular disease.
The Achilles heel of the currently available NNRTls, Dr Miller
said, is the rapidity with which HIV may develop resistance
to these agents. Strict adherence is therefore essential for
long-term success of an NNRTI-containing regimen as even
single-dose nevirapine used to prevent perinatal HIV
transmission has been associated with significant rates of
resistance. Since resistance to one NNRTI generally confers
full cross-resistance to other drugs in the same class, it is
generally not possible to change
from one NNRTI to another when a
patient fails therapy. Recently, new
NNRTI resistance mutations have
been described in non-subtype 8
HIV 'African strains' and it is
thought that this may confer
additional virulence to the virus.
There is currently much debate
about the appropriate use of
NNRTls. Although these agents are
most widely used as first-line
therapy, some opinion leaders
prefer initiating treatment with
protease inhibitor-based HAART,
reserving NNRTls as potent
elements of a salvage regimen.
Provided the virus remains NNRTI-
susceptible, both approaches yield
favourable clinical, vlrological and
immunological outcomes.
In closing, Dr Miller presented
preliminary data on a range of new
third-generation NNRTls that are
'resistance repellent: Early
laboratory and clinical studies
confirm that these drugs possess
potent activity against a broad
range of HIV isolates, including
many that are resistant to
nevirapine and efavirenz. They
offer the tantalising promise of
being able to prescribe a new NNRTI despite resistance to
older compounds. In addition, they have properties that
allow them to be adapted for use in unique situations, such
as topical microbicides or 'chemical condoms' within the
female genital tract.
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